However, the high cost of SGLT2 inhibitors suggests that they will be infrequently used in LMICs at present and reinforces the opportunity cost associated with detecting additional cases of CKD as opposed to treating known cases. This evidence concerns the gene SLC5A2 and chronic kidney disease.